| Literature DB >> 26221117 |
Thais Sebastiana Porfida Ferreira1, Maria Roberta Felizardo1, Debora Dirani Sena de Gobbi1, Marina Moreno1, Andrea Micke Moreno1.
Abstract
Cats are often described as carriers of Pasteurella multocida in their oral microbiota. This agent is thought to cause pneumonia, conjunctivitis, rhinitis, gingivostomatitis, abscess and osteonecrosis in cats. Human infection with P. multocida has been described in several cases affecting cat owners or after cat bites. In Brazil, the cat population is approximately 21 million animals and is increasing, but there are no studies of the presence of P. multocida in the feline population or of human cases of infection associated with cats. In this study, one hundred and ninety-one healthy cats from owners and shelters in São Paulo State, Brazil, were evaluated for the presence of P. multocida in their oral cavities. Twenty animals were positive for P. multocida , and forty-one strains were selected and characterized by means of biochemical tests and PCR. The P. multocida strains were tested for capsular type, virulence genes and resistance profile. A total of 75.6% (31/41) of isolates belonged to capsular type A, and 24.4% (10/41) of the isolates were untypeable. None of the strains harboured toxA, tbpA or pfhA genes. The frequencies of the other genes tested were variable, and the data generated were used to build a dendrogram showing the relatedness of strains, which were clustered according to origin. The most common resistance profile observed was against sulfizoxazole and trimethoprim-sulphamethoxazole.Entities:
Keywords: Pasteurela multocida; cat; isolation; resistance; virulence genes
Mesh:
Substances:
Year: 2015 PMID: 26221117 PMCID: PMC4512071 DOI: 10.1590/S1517-838246120140084
Source DB: PubMed Journal: Braz J Microbiol ISSN: 1517-8382 Impact factor: 2.476
Distribution of genes evaluated in single gene PCR or multiplex PCR and the size of the expected products.
| PCR | Gene | Amplicon (bp) |
|---|---|---|
| E1 | kmt 1 | 560 |
| C1 | hyaD-hyaC, bcbD, dcbF, ecbJ, fcbD | 1.044, 760, 657, 511, 851 |
| FV1 | hgbA, ptfA, hgbB, exbBD/ tonB | 419, 488, 788, 1144 |
| FV2 | nanH, psl, nanB | 360, 439, 584 |
| FV3 | ompH, oma87 | 438, 949 |
| F4 | pfhA, sodC | 275, 235 |
| FV5 | sodA | 361 |
| FV 6 | tbPA | 728 |
| FV 7 | fimA, pmHAS, OmpA | 866, 430, 201 |
| FV 8 | hsf1, hsf2, fur | 654, 433, 244 |
| FV 9 | tadD, plpB | 416, 282 |
Frequency of protein-coding genes and virulence factors in P. multocida strains isolated from cats.
| Gene | Virulence factor | No of positives (%) |
|---|---|---|
|
| Dermonecrotic Toxin | 0/41 (0.0) |
|
| Filamentous hemagglutinin | 0/41 (0.0) |
|
| Hemoglobin-binding protein | 25/41 (60.9) |
|
| Hemoglobin-binding protein | 35/41 (85.3) |
|
| Iron acquisition | 39/41 (95.1) |
|
| Neuraminidase | 34/41 (82.9) |
|
| Porin | 38/41 (92.6) |
|
| Neuraminidase | 40/41 (97.5) |
|
| Outer membrane protein H | 39/41 (95.1) |
|
| Outer membrane protein 87 | 41/41 (100.0) |
|
| Type 4 fimbriae | 26/41 (63.4) |
|
| Superoxide dismutase | 35/41 (85.3) |
|
| Superoxide dismutase | 21/41 (51.2) |
|
| Transferrin binding protein | 0/41 (0.0) |
|
| Fimbriae | 25/41 (60.5) |
|
| Autotransporter Adhesin | 5/41/ (12.1) |
|
| Autotransporter Adhesin | 11/41 (26.8) |
|
| Putative nonspecific tight adherence protein D | 9/41 (21.9) |
|
| Ferric uptake regulation protein | 7/41 (17.0) |
|
| Hyaluronan synthase | 26/41 (63.4) |
|
| Outer membrane protein A | 14/41 (34.1) |
|
| Lipoprotein B | 20/41 (48.7) |
Figure 1Dendrogram representing the relatedness of P. multocida strains isolated from cats according to their virulence profile.
Frequency of antimicrobial resistance in P. multocida strains isolated from cats, disk content and breakpoints used in this study.
| Antimicrobial | Disk content (μg) |
Zone Diameter Breakpoints
| N ∘ of resistant strains (%) | ||
|---|---|---|---|---|---|
|
| |||||
| S | I | R | |||
| Ampicillin | 10 | ≥ 17 | 14–16 | ≤ 28 | 0/41 (0.0) |
| Ceftiofur | 30 | ≥ 21 | 18–20 | ≤ 17 | 0/41 (0.0) |
| Cotrimoxazole | 1.25/23.75 | ≥ 16 | 11–15 | ≤ 10 | 31/41 (75.6) |
|
Doxycycline
| 30 | ≥ 16 | 13–15 | ≤ 12 | 0/41 (0.0) |
| Enrofloxacin | 5 | ≥ 23 | 17–22 | ≤ 16 | 1/41 (2.4) |
|
Norfloxacin
| 10 | ≥ 17 | 13–16 | ≤ 12 | 1/41 (2.4) |
|
Ciprofloxacin
| 5 | ≥ 21 | 16–20 | ≤ 15 | 1/41 (2.4) |
| Erythromycin | 15 | ≥ 23 | 14–22 | ≤ 13 | 2/41 (4.9) |
| Florfenicol | 30 | ≥ 22 | 19–21 | ≤ 18 | 0/41 (0.0) |
| Penicillin | 10 | ≥ 29 | - | ≤ 28 | 3/41 (7.3) |
| Sulfizoxazole | 300 | ≥ 17 | 13–16 | ≤ 12 | 25/41 (60.9) |
| Tetracycline | 30 | ≥ 19 | 15–18 | ≤ 14 | 0/41 (0.0) |
Trimethoprim/sulphamethoxazole.
Breakpoints from CLSI - M100- S19 (2009).